Drug intelligence / Profile preview

NX-86

Development stage: Preclinical
Lead developer: Paradox Immunotherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

NX-86 is a specialized monoclonal antibody being developed by Paradox Immunotherapeutics for the treatment of neurodegenerative diseases. Currently in the discovery phase, the drug is part of Paradox's focus on protein misfolding diseases, where they leverage monoclonal antibody therapies to target pathological protein aggregates. While the specific molecular target for NX-86 remains undisclosed, the company's broader pipeline includes therapies for various forms of amyloidosis, suggesting a similar approach for neurodegeneration.

Beyond the preview

Go deeper on NX-86.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NX-86.

Explore the full profile